Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine
Vansteenkiste, J. F., Vandebroek, J. E., Nackaerts, K. L., Weynants, P., Valcke, Y. J., Verresen, D. A., Devogelaere, R. C., Marien, S. A., Humblet, Y. P., Dams, N. L.
Published in Annals of oncology (01.09.2001)
Published in Annals of oncology (01.09.2001)
Get full text
Journal Article
Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation in patients with unresectable stage III non-small-cell lung cancer (NSCLC): FEV1 as prognostic marker
Germonpré, P. R., Janssens, A., Van Moorter, L., Verresen, D., Galdermans, D., Devogelaere, R., Ottevaere, H., Mentens, Y., De Pooter, C., Goor, C.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article